Economic Outcomes Associated with Switching Individuals with Schizophrenia between Risperidone and Olanzapine

Findings from a Large US Claims Database

Zhongyun Zhao, Madhav Namjoshi, Beth L. Barber, Danielle L. Loosbrock, Sandra L. Tunis, Baojin Zhu, Alan Breier

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia. Methods: Using a large, integrated medical service and pharmacy claims database, 244 individuals diagnosed with schizophrenia (International Classification of Diseases [9th revision]: 295.xx) who switched treatment from risperidone to olanzapine (n = 202) or from olanzapine to risperidone (n = 42) were identified. Changes in medication use patterns and treatment costs (1999 values) per patient from the pre- to the post-switch period were evaluated. McNemar's tests were used to compare changes in use of antiparkinsonian, antidiabetic and antihyperlipidaemic agents and typical antipsychotics, while the Wilcoxon signed rank tests were applied to examine changes in treatment costs. Results: After switching from risperidone to olanzapine, the percentage of patients using concomitant antiparkinsonian agents and typical antipsychotics decreased significantly from 30.20% to 21.29% (p = 0.0094) and from 30.69% to 18.32% (p = 0.0006), respectively. There was no significant change in the use of antidiabetic or antihyperlipidaemic drugs. For mental health-related treatment, annualised pharmaceutical costs increased by $US1761 (from $US1829 to $US3590, p <0.0001) but medical service costs decreased by $US3511 (from $US11 292 to $US7781, p = 0.0036), driven primarily by significantly lower emergency room care and hospital outpatient costs. This resulted in no significant change in overall mental healthcare costs. Similar results were observed with total healthcare costs. In contrast, after switching from olanzapine to risperidone there was no significant change in treatment patterns for any of the medications assessed or in healthcare costs (mental healthcare-related or total), despite a significant decrease in mental health-related pharmaceutical costs. Conclusions: Switching from risperidone to olanzapine was associated with improved medication use patterns for antiparkinsonian and typical antipsychotic agents. While both mental health and total healthcare pharmaceutical costs increased significantly, this was not associated with a significant increase in overall mental health and total healthcare costs. These outcomes, however, were not evidenced in patients switched from olanzapine to risperidone.

Original languageEnglish (US)
Pages (from-to)157-164
Number of pages8
JournalCNS Drugs
Volume18
Issue number3
DOIs
StatePublished - 2004

Fingerprint

olanzapine
Risperidone
Health Care Costs
Schizophrenia
Economics
Databases
Antiparkinson Agents
Antipsychotic Agents
Mental Health
Hypolipidemic Agents
Hypoglycemic Agents
Costs and Cost Analysis
Pharmaceutical Preparations
Pharmaceutical Services
Hospital Costs
Emergency Medical Services
International Classification of Diseases
Therapeutics
Nonparametric Statistics
Hospital Emergency Service

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Economic Outcomes Associated with Switching Individuals with Schizophrenia between Risperidone and Olanzapine : Findings from a Large US Claims Database. / Zhao, Zhongyun; Namjoshi, Madhav; Barber, Beth L.; Loosbrock, Danielle L.; Tunis, Sandra L.; Zhu, Baojin; Breier, Alan.

In: CNS Drugs, Vol. 18, No. 3, 2004, p. 157-164.

Research output: Contribution to journalArticle

Zhao, Zhongyun ; Namjoshi, Madhav ; Barber, Beth L. ; Loosbrock, Danielle L. ; Tunis, Sandra L. ; Zhu, Baojin ; Breier, Alan. / Economic Outcomes Associated with Switching Individuals with Schizophrenia between Risperidone and Olanzapine : Findings from a Large US Claims Database. In: CNS Drugs. 2004 ; Vol. 18, No. 3. pp. 157-164.
@article{037b3766d0af4f6aa1758c9a07bfeca7,
title = "Economic Outcomes Associated with Switching Individuals with Schizophrenia between Risperidone and Olanzapine: Findings from a Large US Claims Database",
abstract = "Objectives: To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia. Methods: Using a large, integrated medical service and pharmacy claims database, 244 individuals diagnosed with schizophrenia (International Classification of Diseases [9th revision]: 295.xx) who switched treatment from risperidone to olanzapine (n = 202) or from olanzapine to risperidone (n = 42) were identified. Changes in medication use patterns and treatment costs (1999 values) per patient from the pre- to the post-switch period were evaluated. McNemar's tests were used to compare changes in use of antiparkinsonian, antidiabetic and antihyperlipidaemic agents and typical antipsychotics, while the Wilcoxon signed rank tests were applied to examine changes in treatment costs. Results: After switching from risperidone to olanzapine, the percentage of patients using concomitant antiparkinsonian agents and typical antipsychotics decreased significantly from 30.20{\%} to 21.29{\%} (p = 0.0094) and from 30.69{\%} to 18.32{\%} (p = 0.0006), respectively. There was no significant change in the use of antidiabetic or antihyperlipidaemic drugs. For mental health-related treatment, annualised pharmaceutical costs increased by $US1761 (from $US1829 to $US3590, p <0.0001) but medical service costs decreased by $US3511 (from $US11 292 to $US7781, p = 0.0036), driven primarily by significantly lower emergency room care and hospital outpatient costs. This resulted in no significant change in overall mental healthcare costs. Similar results were observed with total healthcare costs. In contrast, after switching from olanzapine to risperidone there was no significant change in treatment patterns for any of the medications assessed or in healthcare costs (mental healthcare-related or total), despite a significant decrease in mental health-related pharmaceutical costs. Conclusions: Switching from risperidone to olanzapine was associated with improved medication use patterns for antiparkinsonian and typical antipsychotic agents. While both mental health and total healthcare pharmaceutical costs increased significantly, this was not associated with a significant increase in overall mental health and total healthcare costs. These outcomes, however, were not evidenced in patients switched from olanzapine to risperidone.",
author = "Zhongyun Zhao and Madhav Namjoshi and Barber, {Beth L.} and Loosbrock, {Danielle L.} and Tunis, {Sandra L.} and Baojin Zhu and Alan Breier",
year = "2004",
doi = "10.2165/00023210-200418030-00002",
language = "English (US)",
volume = "18",
pages = "157--164",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Economic Outcomes Associated with Switching Individuals with Schizophrenia between Risperidone and Olanzapine

T2 - Findings from a Large US Claims Database

AU - Zhao, Zhongyun

AU - Namjoshi, Madhav

AU - Barber, Beth L.

AU - Loosbrock, Danielle L.

AU - Tunis, Sandra L.

AU - Zhu, Baojin

AU - Breier, Alan

PY - 2004

Y1 - 2004

N2 - Objectives: To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia. Methods: Using a large, integrated medical service and pharmacy claims database, 244 individuals diagnosed with schizophrenia (International Classification of Diseases [9th revision]: 295.xx) who switched treatment from risperidone to olanzapine (n = 202) or from olanzapine to risperidone (n = 42) were identified. Changes in medication use patterns and treatment costs (1999 values) per patient from the pre- to the post-switch period were evaluated. McNemar's tests were used to compare changes in use of antiparkinsonian, antidiabetic and antihyperlipidaemic agents and typical antipsychotics, while the Wilcoxon signed rank tests were applied to examine changes in treatment costs. Results: After switching from risperidone to olanzapine, the percentage of patients using concomitant antiparkinsonian agents and typical antipsychotics decreased significantly from 30.20% to 21.29% (p = 0.0094) and from 30.69% to 18.32% (p = 0.0006), respectively. There was no significant change in the use of antidiabetic or antihyperlipidaemic drugs. For mental health-related treatment, annualised pharmaceutical costs increased by $US1761 (from $US1829 to $US3590, p <0.0001) but medical service costs decreased by $US3511 (from $US11 292 to $US7781, p = 0.0036), driven primarily by significantly lower emergency room care and hospital outpatient costs. This resulted in no significant change in overall mental healthcare costs. Similar results were observed with total healthcare costs. In contrast, after switching from olanzapine to risperidone there was no significant change in treatment patterns for any of the medications assessed or in healthcare costs (mental healthcare-related or total), despite a significant decrease in mental health-related pharmaceutical costs. Conclusions: Switching from risperidone to olanzapine was associated with improved medication use patterns for antiparkinsonian and typical antipsychotic agents. While both mental health and total healthcare pharmaceutical costs increased significantly, this was not associated with a significant increase in overall mental health and total healthcare costs. These outcomes, however, were not evidenced in patients switched from olanzapine to risperidone.

AB - Objectives: To assess the impact of switching atypical antipsychotic treatment [from (i) risperidone to olanzapine or (ii) olanzapine to risperidone] on medication use patterns and treatment costs for individuals with schizophrenia. Methods: Using a large, integrated medical service and pharmacy claims database, 244 individuals diagnosed with schizophrenia (International Classification of Diseases [9th revision]: 295.xx) who switched treatment from risperidone to olanzapine (n = 202) or from olanzapine to risperidone (n = 42) were identified. Changes in medication use patterns and treatment costs (1999 values) per patient from the pre- to the post-switch period were evaluated. McNemar's tests were used to compare changes in use of antiparkinsonian, antidiabetic and antihyperlipidaemic agents and typical antipsychotics, while the Wilcoxon signed rank tests were applied to examine changes in treatment costs. Results: After switching from risperidone to olanzapine, the percentage of patients using concomitant antiparkinsonian agents and typical antipsychotics decreased significantly from 30.20% to 21.29% (p = 0.0094) and from 30.69% to 18.32% (p = 0.0006), respectively. There was no significant change in the use of antidiabetic or antihyperlipidaemic drugs. For mental health-related treatment, annualised pharmaceutical costs increased by $US1761 (from $US1829 to $US3590, p <0.0001) but medical service costs decreased by $US3511 (from $US11 292 to $US7781, p = 0.0036), driven primarily by significantly lower emergency room care and hospital outpatient costs. This resulted in no significant change in overall mental healthcare costs. Similar results were observed with total healthcare costs. In contrast, after switching from olanzapine to risperidone there was no significant change in treatment patterns for any of the medications assessed or in healthcare costs (mental healthcare-related or total), despite a significant decrease in mental health-related pharmaceutical costs. Conclusions: Switching from risperidone to olanzapine was associated with improved medication use patterns for antiparkinsonian and typical antipsychotic agents. While both mental health and total healthcare pharmaceutical costs increased significantly, this was not associated with a significant increase in overall mental health and total healthcare costs. These outcomes, however, were not evidenced in patients switched from olanzapine to risperidone.

UR - http://www.scopus.com/inward/record.url?scp=1442286378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442286378&partnerID=8YFLogxK

U2 - 10.2165/00023210-200418030-00002

DO - 10.2165/00023210-200418030-00002

M3 - Article

VL - 18

SP - 157

EP - 164

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 3

ER -